Nightingale Health Plc – Managers’ transactions – Ilkka Laurila

Managers' Transactions, 17 October 2023 at 10.15 a.m. (EEST)

____________________________________________ 

Person subject to the notification requirement 

Name: Ilkka Laurila 

Position: Member of the Board/Deputy member 

Issuer: Nightingale Health Oyj 

LEI: 743700WUIPC24LVMLO66 

Notification type: INITIAL NOTIFICATION 

Reference number: 40784/5/4 

____________________________________________ 

Transaction date: 2023-10-12 

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME) 

Instrument type: SHARE 

ISIN: FI4000490875 

Nature of transaction: ACQUISITION 

Transaction details 

(1): Volume: 420 Unit price: 1.084 EUR 

(2): Volume: 4580 Unit price: 1.096 EUR 

(3): Volume: 2000 Unit price: 1.118 EUR 

(4): Volume: 1000 Unit price: 1.12 EUR 

Aggregated transactions (4): 

Volume: 8000 Volume weighted average price: 1.10387 EUR 

For further information, please contact: 

Teemu Suna, CEO 
ir@nightingalehealth.com 

Certified Adviser: 
Oaklins Merasco Ltd, tel. +358 9 6129 670 

About Nightingale Health 

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years. 

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 25 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 450 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com

Tags: